BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences:
A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the PepGen website at https://investors.pepgen.com/. Replays of the webcasts will be available on the PepGen website for 90 days following the presentation dates.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
Investor Contact
Laurence Watts
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Sarah Sutton
Argot Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.11 |
| Daily Change: | -0.38 -8.46 |
| Daily Volume: | 113,176 |
| Market Cap: | US$133.940M |
November 07, 2024 October 08, 2024 August 08, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
